Abstract

The diaminedithiol (N2S2) tetradentate ligand constitutes a useful chelating molecule for preparing 99mTc-labeled compounds of high in vivo stability in high radiochemical yields. However, since the thiol groups in the N2S2 ligand are easy to be oxidized to disulfide bonds, they need to be protected with an appropriate protecting group, which hinders the broad applications of the N2S2 ligand for radiopharmaceuticals. In this study, a Zn chelate of N2S2 was evaluated as a precursor for purification-free 99mTc-labeled N2S2 under the mild and simple procedure. Zn-N2S2 was prepared by reacting Zn acetate with N2S2, and the Zn-N2S2 remained stable under aerobic conditions at room temperature. 99mTc-N2S2 was obtained over 90% radiochemical yields at room temperature by a one-pot reaction, consisting of Zn-N2S2 (10−5 M), 99mTcO4−, ethylenediaminetetraacetic acid (EDTA), and a reducing agent (Sn2+) at pH = 5.5 to 7.5. 99mTc-N2S2 was also obtained over 90% radiochemical yields when the reaction was conducted in the presence of an equimolar amount of IgG antibody. These findings indicate the Zn complex of N2S2 ligand constitutes a stable and useful precursor to prepare 99mTc-labeled N2S2 compounds in high yields under the mild and simple procedure.

Highlights

  • The growth and broad applications of diagnostic nuclear medicine have been mainly driven by the artificial radionuclide, technetium-99m (99m Tc), due to its availability from a portable 99 Mo-99m Tc generator system and its almost ideal physical properties for external imaging

  • The N2 S2 ligand 6 was synthesized according to the procedure of Ohmomo et al as shown in Scheme 1. 4-(Methoxyphyenyl)methanethiol 1 was reacted with ethyl 2-bromo-2-methyl propanoate 2 to prepare 3, followed by the condensation with ethylenediamine to provide 4

  • The Zn-N2 S2 remained stable at room temperature under aerobic conditions over several days

Read more

Summary

Introduction

The growth and broad applications of diagnostic nuclear medicine have been mainly driven by the artificial radionuclide, technetium-99m (99m Tc), due to its availability from a portable 99 Mo-99m Tc generator system and its almost ideal physical properties for external imaging. Recent efforts are being made to develop radiopharmaceuticals derived from positron emitters such as 11 C and 18 F, over 70% of diagnostic practices are still conducted with 99m Tc. The cost-effectiveness of 99m Tc-based radiopharmaceuticals contributes to the medical economy in both developed and developing countries. 99m Tc will continue to be used as one of the essential radionuclides for diagnostic nuclear medicine. Radioactive rhenium (186 Re and 188 Re), the congener of Tc, emits beta rays appropriate to targeted radiotherapy to form radiotheranostic pairs with their 99m Tc counterparts due to the chemical analogy between Tc and Re. further development of 99m Tc-radiopharmaceuticals constitutes a crucial issue for cost-effective and successful patient management

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call